SCHEMBL3013015

SCHEMBL3013015

O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)N1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.52
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
ALDH1A1 P00352 3/20 0.50
TSHR P16473 1/20 0.50
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GPR6 P46095 1/20 0.40
LMNA P02545 5/20 0.40
HTT P42858 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 3/20 0.40
HTR6 P50406 1/20 0.39
HSD11B1 P28845 1/20 0.38
POLB P06746 1/20 0.38
GBA1 P04062 1/20 0.38
PKM P14618 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008733 0.93 L3MBTL1 (0.50) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL17510140 0.93 RAB9A (0.46) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL3012814 0.91 MEN1 (0.48) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL3013621 0.91 ALDH1A1 (0.48) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL3010628 0.91 L3MBTL1 (0.50) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL3017970 0.91 MEN1 (0.50) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL3002593 0.90 MEN1 (0.46) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL3007412 0.90 MEN1 (0.46) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL3007233 0.90 MEN1 (0.49) RAB9AMEN1KMT2AALDH1A1TSHR
SCHEMBL3022728 0.89 MEN1 (0.47) RAB9AMEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.